 LAUSANNE, Switzerland--BUSINESS WIRE--ADC Therapeutics SA NYSE: ADCT, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates ADCs to treat hematological malignancies and solid tumors, today announced that the European Commission has granted Orphan Drug Designation to ZYNLONTA, a CD19-targeted ADC, for the treatment of diffuse large B-cell lymphoma DLBCL. This Orphan Drug Designation recognizes the significant unmet need in patients with diff 